Figure 1—
Figure 1—
Changes in intrahepatic (A) and intramyocellular (B) lipid content in three patients with generalized lipodystrophy treated with human recombinant leptin for 8–10 months. The corresponding changes in insulin sensitivity, measured as the rate of glucose disappearance during the insulin tolerance test (K value) are shown in C.
In this Issue
April 2021, 44(4)
